
Screened
N=358
Discontinued 1
Did not meet entry criteria 1
OL treatment with milnacipran
N=357
Discontinued 17
Did not meet entry criteria 4
Adverse event 2
Withdrawal of consent 7
Lost to follow-up 3
Other reasons 1
Responders
N=151
Nonresponders[a]
N=189
Randomized to placebo
n=51
Randomized to milnacipran
n=100
Discontinued
n=20 (39.2%)
Discontinued
n=25 (25.0%)
LTR[b]
n=18 (35.3%)
LTR[b]
n=23 (23.0%)
Withdrew consent
n=2 (3.9%)
Adverse event
n=2 (2.0%)
Completed study[c]
n=31 (60.8%)
Completed study[c]
n=75 (75.0%)
Included in analyses[d]
n=50 (98.0%)
Included in analyses
n=100 (100%)